Bender Robert & Associates
- SEC CIK
- 0000894300
- Latest filing
- Jul 30, 2026
JNCE holding history
Jounce Therapeutics, Inc. in every 13F filed by Bender Robert & Associates, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
JNCE overviewAll 13F holders of JNCEFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 4
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −10,000−100.0% | Sold out | Holders |
| Q1 2023 | 10,000 | $18.5K | <0.1% | +10,000 | New | Holders |
| Q4 2022 | 0 | $0 | 0.0% | −10,000−100.0% | Sold out | Holders |
| Q3 2022 | 10,000 | $23.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 10,000 | $30.0K | <0.1% | +10,000 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −10,000−100.0% | Sold out | Holders |
| Q1 2021 | 10,000 | $103.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.